Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.
Front Oncol
; 13: 1110689, 2023.
Article
in En
| MEDLINE
| ID: mdl-36793614
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
Front Oncol
Year:
2023
Type:
Article
Affiliation country:
China